The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation.

Authors: Tran HT, Gigl M, Le NP, Dawid C, Lamy E PMID: 34681279 PMCID: PMC8538008 DOI: 10.3390/ph14101055 Abstract To date, there have been rapidly spreading new SARS-CoV-2 "variants of concern". They all contain multiple mutations in the ACE2 receptor recognition site of the spike protein, compared to the original Wuhan sequence, which is of great [...]

Authors: Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Liu J PMID: 34478478 PMCID: PMC8415618 DOI: 10.1371/journal.pone.0257016 Abstract Background: Activation of the immune system is implicated in the Post-Acute Sequelae after SARS-CoV-2 infection (PASC) but the mechanisms remain unknown. Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin II (Ang II) resulting in decreased activation of [...]

Authors: Tomassetti F, Nuccetelli M, Sarubbi S, Gisone F, Ciotti M PMID: 34339963 PMCID: PMC8313542 DOI: 10.1016/j.intimp.2021.108013 Abstract The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high [...]

Authors: Perrella F, Coppola F, Petrone A, Platells C, Montesarchio D, Ravagnan G PMID: 34356672 PMCID: PMC8301781 DOI: 10.3390/biom11071048 Abstract In the search for new therapeutic strategies to contrast SARS-CoV-2, we here studied the interaction of polydatin (PD) and resveratrol (RESV)-two natural stilbene polyphenols with manifold, well known biological activities-with Spike, the viral protein essential [...]

Authors: Clausen TM, Sandoval DR, Spliid CB, PiHl J, Painter CD, Thacker BE et al. PMID: 32970989 PMCID: PMC7489987 DOI: 10.1016/j.cell.2020.09.033 Abstract We show that SARS-CoV-2 spike protein interacts with both cellular heparan sulfate and angiotensin-converting enzyme 2 (ACE2) through its receptor-binding domain (RBD). Docking studies suggest a heparin/heparan sulfate-binding site adjacent to the ACE2-binding [...]

Authors: Magro CM, Mulvey JJ, Laurence J, seshan S, Crowson AN, Harp J PMID: 33058948 PMCID: PMC7550120 DOI: 10.1016/j.humpath.2020.10.002 Abstract The purpose of this study was to examine the deltoid skin biopsy in twenty-three patients with coronavirus disease 2019 (COVID-19), most severely ill, for vascular complement deposition and correlate this with severe acute respiratory syndrome [...]

Authors: Lehrer S, Rheinstein PH PMID: 32871846 PMCID: PMC7652439 DOI: 10.21873/invivo.12134 Abstract Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking [...]

Authors: Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y PMID: 32887634 PMCID: PMC7471641 DOI: 10.1186/s13045-020-00954-7 Abstract Background: Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic state that places them at a dramatically increased lethal risk. Although platelet activation is critical for thrombosis and is responsible for the thrombotic events [...]

Authors: Li MY, Li L, Zhang Y, Wang XS PMID: 32345362 PMCID: PMC7186534 DOI: 10.1186/s40249-020-00662-x Abstract Background: Since its discovery in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 2 180 000 people worldwide and has caused more than 150 000 deaths as of April 16, 2020. SARS-CoV-2, which is [...]